

Rev03
Update: Dec,14,2021

DATASHEET

IL-18 BP, Human

Cat. No.: Z03168

Product Introduction

Species	Human
Protein Construction	IL-18 BP (Thr31-Gly194) Accession # O95998
Purity	> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC
Endotoxin Level	< 0.2 EU/ μ g of protein by gel clotting method
Biological Activity	ED ₅₀ < 30.0 ng/ml, measured in a bioassay using KG-1 cells in the presence of 50.0 ng/ml Human IL-18.
Expression System	CHO
Apparent Molecular Weight	42~44 kDa, on SDS-PAGE under reducing conditions.
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Background

Target Background : Interleukin-18 binding protein, also known as IL-18BP and tadekinig-alfa, is a secreted glycoprotein that contains an Ig-like C2-type domain. It is expressed in heart, lung, placenta and spleen. IL-18BP functions as an inhibitor of the proinflammatory cytokine IL-18. It binds to IL-18, prevents the binding of IL-18 to its receptor, and thus blocks IL-18-induced IFN-gamma production. The complete Ig domain has been shown to mediate the binding and neutralizing properties. IFN-gamma is able to upregulate the expression of IL-18BP, indicating that IL-18 activity is regulated by a feedback mechanism through IL-18BP.

Synonyms : Tadekinig-alfa; IL18BP

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.